GZL and poly-EBV-L clinical characteristics at diagnosis
| Characteristics . | GZL all (N = 50) . | GZL exome (n = 21) . | GZL target (n = 29) . | P* (exome vs target) . | Poly-EBV-L (n = 20) . |
|---|---|---|---|---|---|
| Center | LYSA: n = 44 | LYSA: n = 19 | LYSA: n = 25 | .68 | LYSA: n = 19 |
| BCC: n = 6 | BCC: n = 2 | BCC: n = 4 | BCC: n = 1 | ||
| Age, mean (range), y | 46 (14-90) | (14-76) | (20-90) | .17 | 55 (16-84) |
| Aγε ≥60 y | 14 (28) | 4 (19) | 10 (34) | 8 (40) | |
| F/M, n/n | 25/25 | 13/8 | 12/17 | .15 | 6/14 |
| GZL classification | .95 | Not applicable | |||
| 0 | 8 (16) | 3 (14) | 5 (17) | ||
| 1 | 19 (38) | 8 (38) | 11 (38) | ||
| 2 | 23 (46) | 10 (48) | 13 (45) | ||
| Mediastinal involvement | .3 | ||||
| Thymic | 31 (63) | 15 (71) | 16 (57) | 5 (28) | |
| Nonthymic | 18 (37) | 6 (29) | 12 (43) | 13 (72) | |
| Med-nonthymic | 7 (14) | 2 (10) | 5 (18) | 0 (0) | |
| Nonmediastinal | 11 (23) | 4 (23) | 7 (25) | 13 (72) | |
| NA | 1 | 0 | 1 | 2 | |
| Ann Arbor stage | n = 46 | n = 21 | n = 25 | .23 | n = 16 |
| 1-2 | 24 (52) | 13 (62) | 11 (44) | 7 (44) | |
| 3-4 | 22 (48) | 8 (38) | 14 (56) | 9 (56) | |
| Extranodal site | 19/46 (41) | 6/19 (32) | 13/25 (52) | .17 | 5/16 (31) |
| Spleen | 5 (26)† | 3 † | 3 † | 4 (80)† | |
| Liver | 3 (16)† | 1 † | 2 † | 4 (80)† | |
| Lung | 7 (37)† | 3 † | 4 † | 2 † | |
| Bone marrow | 9 (47)† | 3 † | 6 † | 1 † | |
| LDH above upper limit of normal | 26/46 (59) | 10/20 (50) | 16/24 (67) | .26 | 7/16 (44) |
| Age-adjusted IPI | n = 44 | n = 20 | n = 24 | n = 16 | |
| 0-1 | 26 (61) | 15 (75) | 11 (46) | .06 | 8 (50) |
| 2-3 | 18 (39) | 5 (25) | 13 (54) | 8 (50) |
| Characteristics . | GZL all (N = 50) . | GZL exome (n = 21) . | GZL target (n = 29) . | P* (exome vs target) . | Poly-EBV-L (n = 20) . |
|---|---|---|---|---|---|
| Center | LYSA: n = 44 | LYSA: n = 19 | LYSA: n = 25 | .68 | LYSA: n = 19 |
| BCC: n = 6 | BCC: n = 2 | BCC: n = 4 | BCC: n = 1 | ||
| Age, mean (range), y | 46 (14-90) | (14-76) | (20-90) | .17 | 55 (16-84) |
| Aγε ≥60 y | 14 (28) | 4 (19) | 10 (34) | 8 (40) | |
| F/M, n/n | 25/25 | 13/8 | 12/17 | .15 | 6/14 |
| GZL classification | .95 | Not applicable | |||
| 0 | 8 (16) | 3 (14) | 5 (17) | ||
| 1 | 19 (38) | 8 (38) | 11 (38) | ||
| 2 | 23 (46) | 10 (48) | 13 (45) | ||
| Mediastinal involvement | .3 | ||||
| Thymic | 31 (63) | 15 (71) | 16 (57) | 5 (28) | |
| Nonthymic | 18 (37) | 6 (29) | 12 (43) | 13 (72) | |
| Med-nonthymic | 7 (14) | 2 (10) | 5 (18) | 0 (0) | |
| Nonmediastinal | 11 (23) | 4 (23) | 7 (25) | 13 (72) | |
| NA | 1 | 0 | 1 | 2 | |
| Ann Arbor stage | n = 46 | n = 21 | n = 25 | .23 | n = 16 |
| 1-2 | 24 (52) | 13 (62) | 11 (44) | 7 (44) | |
| 3-4 | 22 (48) | 8 (38) | 14 (56) | 9 (56) | |
| Extranodal site | 19/46 (41) | 6/19 (32) | 13/25 (52) | .17 | 5/16 (31) |
| Spleen | 5 (26)† | 3 † | 3 † | 4 (80)† | |
| Liver | 3 (16)† | 1 † | 2 † | 4 (80)† | |
| Lung | 7 (37)† | 3 † | 4 † | 2 † | |
| Bone marrow | 9 (47)† | 3 † | 6 † | 1 † | |
| LDH above upper limit of normal | 26/46 (59) | 10/20 (50) | 16/24 (67) | .26 | 7/16 (44) |
| Age-adjusted IPI | n = 44 | n = 20 | n = 24 | n = 16 | |
| 0-1 | 26 (61) | 15 (75) | 11 (46) | .06 | 8 (50) |
| 2-3 | 18 (39) | 5 (25) | 13 (54) | 8 (50) |